Search

Elinzanetant

[L53798] Later the same year, it was approved in the US for the same indication. [L54216] … [A274198] On July 23, 2025, it was approved by Health Canada to treat moderate to severe vasomotor symptoms (VMS) associated with menopause.

Methylchloroisothiazolinone

It is found within many commercially available cosmetics, lotions, and makeup removers. … It is also a known dermatological sensitizer and allergen; some of its side effects include flaky or scaly skin, breakouts, redness or itchiness, and moderate to severe swelling in the eye area.

Bromelains

It is considered as a safe food supplement. … It works by selectively inhibiting the biosynthesis of proinflammatory prostaglandins [A27197] and also has analgesic properties, as well as anticancerous and pro-apoptotic effects.

Methionine sulfoximine

Cardamom

Rurioctocog alfa pegol

It was first approved by the European Commission in January 2018.

Corticorelin

It is a type of neurohormone, also called hCRF. … It is made naturally by the hypothalamus (a part of the brain) and can also be made in the laboratory.

Pegunigalsidase alfa

Furthermore, the pegylation of pegunigalsidase alfa promotes higher stability and a longer half-life, allowing it to reach target organs with a lower dose and frequency of administration.

Copper histidinate

It was approved by the US FDA in January 2026 for the treatment of pediatric patients with Menkes disease.[L54993,L54998] … Menkes disease is a rare, X-linked recessive disorder caused by pathogenic variants in the ATP7A gene, which encodes a copper transport protein essential for absorbing dietary copper and transporting it

Cyanocobalamin Co-60

Cyanocobalamin Co-60 was used for the diagnosis of pernicious anemia, but now it is withdrawn from the market in the US for unknown reasons.